CARLSBAD, Calif., Dec. 20, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that its wholly-owned subsidiary, Lifeline Skin Care, Inc. ("Lifeline") is launching multi-media marketing campaigns and two new high-tech products featuring Lifeline’s proprietary stem cell extract and small molecule technologies.
Starting December 2016 Lifeline® Aqueous Gel Serum and Lifeline® Brightening Toner may be purchased through Lifeline website (www.lifelineskincare.com), while Lifeline® ProPlus Advanced Molecular Serum will be available through select spas and medical practices.
The additions of the new products to the Lifeline Skin Care consumer and professional lines is to help to increase collagen and elastin production for faster cell turnover, the next generation solution for aging skin. The products encapsulate advanced antioxidants to keep the ingredients from degrading. This additional step protects and ensures delivery of ingredients that are active. As a result, when they are absorbed into the skin, they can be more effective. Without this encapsulation step, the key ingredients in many anti-aging products are no longer active once the products reach the skin.
As part of the company’s new marketing campaign, both products were recently showcased on Modern Living with kathy ireland® on acclaimed E! Entertainment Network television show with over 98 million cable and satellite subscribers.
Dr. Monica Bonakdar, M.D., Medical Director at Bonakdar Institute and one of the featured experts on Modern Living premier, said “Topical Retinoic Acid family is the most studied group and effective skincare ingredient for anti-aging purposes. Unfortunately, patient compliance with ongoing use is low with many of the Retinoic Acid products available because of the irritation and dryness. Lifeline Small Molecule technology is a superior alternative because it does not cause irritation and dryness. It is effective and results are seen rapidly.”
About Lifeline Skin Care
Lifeline Skin Care develops markets and sells advanced topical anti-aging skin care products based on parthenogenetic (non-embryonic) human stem cell technology developed by International Stem Cell Corporation. Lifeline products are distributed in the USA and internationally through a network of distributors, physicians and spas.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
Safe harbor statement
Statements pertaining to anticipated developments, expected clinical studies (including timing and results), progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.